PROton Therapy for Post Surgical Treatment of GYNecologic Cancer

Description

This is a single institution, multi-center, Phase II, single-arm study, using Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) in the post-surgical, adjuvant setting for definitive treatment of gynecologic cancers. The purpose of this study is to estimate rate of acute clinician-reported gastrointestinal (GI) toxicity using WP PBS PRT in the definitive treatment of gynecologic cancers in the post-surgical, adjuvant setting.

Conditions

Cervical Cancer, Uterine Cancer, Endometrial Cancer

Study Overview

Study Details

Study overview

This is a single institution, multi-center, Phase II, single-arm study, using Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) in the post-surgical, adjuvant setting for definitive treatment of gynecologic cancers. The purpose of this study is to estimate rate of acute clinician-reported gastrointestinal (GI) toxicity using WP PBS PRT in the definitive treatment of gynecologic cancers in the post-surgical, adjuvant setting.

Adjuvant Proton Whole Pelvis Radiation Therapy for Treatment of Post-Surgical Gynecologic Cancers

PROton Therapy for Post Surgical Treatment of GYNecologic Cancer

Condition
Cervical Cancer
Intervention / Treatment

-

Contacts and Locations

Lancaster

Lancaster General Health - Ann B. Barshinger Cancer Institute, Lancaster, Pennsylvania, United States, 17601

Philadelphia

University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Histologically confirmed cervical or endometrial cancer
  • * Indication for adjuvant whole pelvic radiation therapy, with or without systemic therapy
  • * Age of 18 years or older
  • * Written informed consent
  • * ECOG of 0-2 within 3 months of enrolling
  • * Prior course of pelvic radiation
  • * Metastatic disease outside of the pelvis
  • * Active inflammatory bowel disease
  • * Incapacity to provide informed consent

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Abramson Cancer Center at Penn Medicine,

Neil K Taunk, MD, MSCTS, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

Study Record Dates

2026-11